Join the club for FREE to access the whole archive and other member benefits.


Biotechnology company focused on treating neurodegenerative and other age-related diseases

Aging is the dominant risk factor in degenerative diseases. Many of the pressing age-related and neurodegenerative diseases have a profound impact on patients and their caregivers, yet have very limited treatment options. Alkahest has embarked upon a simple but elegant approach to treat disorders of aging by capitalizing on the body’s own natural regulatory and communication mechanisms, leveraging the plasma proteome. The promise of this science, and the potential to make a difference to patients around the world, was the founding principle of Alkahest.

Alkahest’s therapeutic agents stem from a deep understanding of the changing plasma proteome in healthy aging and in age-related diseases. As we age, the majority of our proteins stay the same. But about 15% of our proteins change substantially as we age, or as we contend with disease. It’s these proteins, the chronokines, which inspire Alkahest science. By targeting chronokines, we develop clinical candidates that either increase or decrease the levels of circulating chronokines to promote innate and natural restorative biological processes or discourage pathological, degenerative processes in age-related diseases.

Visit website:



Details last updated 09-Apr-2019

Alkahest Blog Posts

Ambrosia Plasma relaunches - announces improvement in key ageing biomarkers

Ambrosia Plasma relaunches - announces improvement in key ageing biomarkers

The Club interviews Jesse Karmazin, CEO, to find out more about the trial, the FDA warning, and the relaunch

Stanford University optimistic about human rejuvenation

Stanford University optimistic about human rejuvenation

Summary of “Turning back time with emerging rejuvenation Strategies” published in Nature Cell Biology

People at Alkahest

Viktoria Kheifets

Senior Vice President at Alkahest

Steven Braithwaite

CSO at Alkahest, Inc.

Jonas Hannestad

VP Clinical Development at Alkahest, Inc.

Karoly Nikolich

Chairman of the Board of Directors and Chief Executive Officer of Alkahest.

Alkahest News

Reason reports back from Age-Related Disease Therapeutics Summit 2023

Fight Aging! - 16-Jun-2023

Many people believe lots of clinical trials of novel therapeutics targeting mechanisms of aging will start up in the next few years


Super summary of 3rd Annual Longevity Therapeutics Summit (LEAF) - 16-Feb-2021

More and more companies making greater and greater progress - 2021 could be an exciting year


LEAF interviews the Conboys about rejuvenating mice by diluting blood plasma (LEAF) - 16-Jun-2020

This could be a cheap first generation rejuvenation treatment - but wait for clinical trials


Device by Alkahest to treat dialysis-associated dementia

Longevity Technology - 02-Jun-2020

With phase 2 study announced, hopes are up for end-stage renal disease sufferers


Longevity Leaders' latest report on how longevity is disrupting the world

Longevity Leaders (LSX) - 01-Jan-2020

An interesting collection of interviews and white-papers with industry leaders


Chronokines in young blood could be the cure for Alzheimer's

New Atlas - 06-Aug-2019

Plasma proteins to the rescue of good-old memories in Alzheimer's


Oral treatment for wet age-related macular degeneration passes Phase 2a trials

CISION PR Newswire - 17-Dec-2018

Intriguing hint that this treatment may have potential for other age-related diseases


Young blood as a key to living longer

Wired - 09-May-2018

GDF11 is a protein in the blood, which can stimulate cell growth and repair


Young blood does little to reverse Alzheimer’s in first test

Science Magazine - 01-Nov-2017

16 people with mild or moderate Alzheimer’s disease received weekly injections of young plasma. ...


Young blood antiaging trial raises questions

Science - 01-Aug-2016

Ambrosia ( young plasma trial is open to anyone 35 and older. Pa...

Topics mentioned on this page:
Life Extension